After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Akebia Therapeutics Inc. is $305.19M. A total of 3.02 million shares were traded on the day, compared to an average of 1.96M shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, AKBA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 4 SELLs from insiders. Insiders purchased 1,280,000 shares during that period but sold 285,798.
In the most recent transaction, Butler John P. sold 46,570 shares of AKBA for 1.58 per share on Feb 29. After the transaction, the CEO and President now owns 2,044,580 company shares. In a previous transaction on Feb 29, Dahan Michel sold 8,661 shares at 1.58 per share. AKBA shares that SVP, Chief Operating Officer owns now total 706,932.
Among the insiders who sold shares, Burke Steven Keith disposed of 7,169 shares on Feb 29 at a per-share price of $1.58. This resulted in the SVP, Chief Medical Officer holding 695,840 shares of AKBA after the transaction. In another insider transaction, Hadas Nicole R. sold 5,974 shares at $1.58 per share on Feb 29. Company shares held by the SVP, Chief Legal Officer now total 663,259.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, AKBA has a high of $1.84 and a low of $0.49.
As of this writing, AKBA has an earnings estimate of -$0.04 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.06. The company reported an EPS of -$0.06 in the last quarter, which was -200.00% lower than expectations of -$0.02.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. AKBA’s latest balance sheet shows that the firm has $149.80M in Cash & Short Term Investments as of fiscal 2021. There were $136.05M in debt and $261.05M in liabilities at the time. Its Book Value Per Share was -$0.21, while its Total Shareholder’s Equity was $74.01M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKBA is Buy with a score of 4.50.
